Key result
AF ablation in HFpEF lacks robust clinical trial data.
Why the study?
The role of AF ablation in the management of HFpEF remains an under-investigated issue with no robust clinical trial data.
This review discusses the mechanistic and observational evidence both for and against performing atrial fibrillation ablation in patients with HFpEF, highlighting the current lack of robust clinical trial data.
Answers are grounded in this paper and cite their sources.
Current evidence does not support routine AF ablation in HFpEF; leaves open potential benefits pending robust RCTs.
The role of atrial fibrillation (AF) ablation in the management of heart failure with preserved ejection fraction (HFpEF) remains an under investigated issue with no robust clinical trials data. This controversy reviews the evidence for and against AF ablation in this complex condition from two different perspectives reviewing mechanistic and observational evidence aswell as proposing future directions for research in the field.
No takes yet. Share an insight, caveat, or question.
Biase et al. (2026) conducted a review in Atrial fibrillation and heart failure with preserved ejection fraction (HFpEF). Atrial fibrillation ablation was evaluated. Atrial fibrillation ablation in patients with HFpEF remains an under-investigated topic with no robust clinical trial data currently available.
Synapse has enriched 10 related papers. Consider them for comparative context: